BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

MAGL inhibition limits GPNMB+ foamy microglia in multiple sclerosis

BC Staff
June 10, 2026 9:57 PM UTC

BCIQ Company Profiles

Leiden University

University of Amsterdam

BCIQ Target Profiles

Glycoprotein NMB (GPNMB)

Monoglyceride lipase (MGLL) (MAGL)

BCIQ Company Profiles

Leiden University

University of Amsterdam

BCIQ Target Profiles

Glycoprotein NMB (GPNMB)

Monoglyceride lipase (MGLL) (MAGL)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2026 BioCentury Inc. All Rights Reserved.
Copyright © 2026 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS